Video Highlights
1:43 Ann Melvin, MD, MPH
3:03 Jessica Islam, PhD, MPH
5:36 Parastu Kasaie, PhD
6:48 Patricia de los Rios
What is the Impact of PrEP and ART on HIV Prevention?
This is our inaugural segment for our new video series, 1 Big Question, where we ask the medical community a question about a significant infectious disease topic and get feedback from them.
Video Player is loading.
Welcome to our series, 1 Big Question, which asks 1 question to the medical community and we get their feedback on an important infectious disease topic.
In this episode, our 1 Big Question is: With the greater adaption of pre-exposure prophylaxis (PrEP) therapy and the significant impact antiretroviral therapy (ART) has had, do you think medicine is doing a better job at HIV care and prevention?
We interviewed Ann Melvin, MD, MPH, director of HIV Program, Seattle Children’s Hospital; Jessica Islam, PhD, MPH, epidemiologist, Moffitt Cancer Center; Parastu Kasaie, PhD, assistant scientist, Johns Hopkins Bloomberg School of Public Health; and Patricia de los Rios, Global Medical Affairs director, ViiV Healthcare.
Check out the video to hear their insights.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Recent Videos
Considering the Impact of Crop Spraying and Antifungal Resistance
Psychiatric Symptoms Emerging Years After Infections Like Lyme and Tick-Borne Infections
Deciphering Similarities and Differences in Antifungal and Antibiotic Development
Fidaxomicin Tied to Lower C difficile Recurrence in Immunocompromised Patients
'Tis the Season: Addressing Tick-Borne Illnesses
Impact of Obesity on Antibiotic Treatment Outcomes
Fidaxomicin Reduces Recurrence Risk in High-Risk C difficile Infections
Ceftolozane/Tazobactam Shows Strong Activity Against ESBL E coli, But Gaps Remain for K pneumoniae
Vancomycin Loading Doses Improve Target Timing and Safety in 61,000+ Cases
No Significant Difference Between Doxycycline and Minocycline for Bone and Joint Infections
Related Content
